<DOC>
	<DOCNO>NCT01988883</DOCNO>
	<brief_summary>A common complaint among patient Postural Tachycardia Syndrome ( POTS ) `` brain fog '' difficulty concentrate . This problem poorly understood . The purpose study well understand cognitive dysfunction associate POTS , determine optimal treatment strategy condition . In study , investigator test hypothesis acute administration psychostimulant drug modafinil improve seat measure cognitive function patient POTS .</brief_summary>
	<brief_title>Modafinil Cognitive Function POTS</brief_title>
	<detailed_description>Postural Tachycardia Syndrome ( POTS ) one frequent form chronic orthostatic intolerance affect estimate 500,000 people United States alone . This disorder common source disability young adult , strong predilection premenopausal woman . POTS characterize excessive increase heart rate ( &gt; 30 bpm ) assume upright position associate orthostatic symptom relieve lie . These symptom include palpitation , chest pain , lightheadedness dizziness , blur vision , nausea fatigue . In addition , POTS patient commonly report mental cloud `` brain fog '' even lie seat , pose significant limitation daily life . Although mental cloud almost universal complaint among POTS patient , phenomenon poorly understood . As result , optimal treatment strategy manage cognitive dysfunction condition remain unknown . The purpose study well define mental clouding associate POTS determine whether psychostimulant modafinil viable therapeutic option improve cognitive function patient . The investigator hypothesize acute modafinil administration improve seat measure cognitive function POTS patient . The specific aim : 1 . To assess whether acute modafinil improves seat measure cognitive function , particularly measure attention executive function , POTS patient compare placebo . 2 . To assess whether propranolol , either alone active control combination modafinil mitigate potential heart rate increase , improve cognitive function POTS . Patients study 4 separate day oral administration : placebo , modafinil ( 200 mg ) , propranolol ( 20 mg ) combination modafinil ( 200 mg ) propranolol ( 20 mg ) . The order administration randomize double-blind manner . Patients seat study cognitive test begin approximately 2.5 hour medication administration . Cognitive test consist CogState computerize brief battery . Patients also ask stand 10 minute ( long tolerate ) 1 , 3 4 hour post medication , cognitive test repeat stand 4 hour time point .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Males female race age 18 60 year Diagnosed POTS Vanderbilt Autonomic Dysfunction Center base follow consensus criterion : ( ) increase heart rate ≥ 30 beat per minute within 10 minute change supine stand position ; ( b ) absence orthostatic hypotension ( defined decrease systolic blood pressure ≥ 20 mmHg diastolic blood pressure ≥ 10 mmHg upon stand ) ; ( c ) chronic symptom ( ≥ 6 month ) consistent POTS worse stand relieve lie Able willing provide inform consent Overt cause POTS acute dehydration bed rest deconditioning Patients take serotoninnorepinephrine reuptake inhibitor ( SNRIs ) norepinephrine transporter ( NET ) inhibitor Known allergy contraindication study medication Pregnancy breastfeed Inability give withdraw inform consent Other factor investigator 's opinion would prevent subject complete study protocol poor compliance previous study Asthma ( due contraindication propranolol asthma patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Postural Tachycardia Syndrome</keyword>
	<keyword>Tachycardia</keyword>
	<keyword>Orthostatic Intolerance</keyword>
	<keyword>Autonomic Nervous System Diseases</keyword>
	<keyword>Primary Dysautonomias</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Modafinil</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Neurobehavioral Manifestations</keyword>
	<keyword>Neurologic Manifestations</keyword>
	<keyword>Cognitive Symptoms</keyword>
	<keyword>Neuropsychological Tests</keyword>
</DOC>